49 results
S-8
EX-5.1
BIAF
BioAffinity Technologies Inc
5 Jun 24
Registration of securities for employees
4:30pm
) the Plan. We have not performed any independent investigation other than the document examination described. We have assumed and relied
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
.
Patient enrollment is affected by many other factors, including:
the severity of the disease under investigation;
the patient eligibility criteria … related to the product, patient population, phase of investigation, trial sites, and investigators, and other aspects of a clinical trial
POS AM
n7q42fxlswy
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-1.1
7j7m0rx
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-4.2
gwdljptb1ibbb
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-4.1
eqg4dfagkgjlv5
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
7dggvuodu2wv
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
t0ng5lz
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
wwzpky3xs0ipi ui
7 Mar 24
Prospectus supplement for primary offering
9:57pm
8-K
EX-10.1
26124r
31 Jan 24
Departure of Directors or Certain Officers
4:05pm
424B5
n62pz
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
9y25h03e
16 Nov 23
Shelf registration
5:23pm
S-3
EX-4.3
eieezqs0v
16 Nov 23
Shelf registration
5:23pm
S-8
EX-5.1
c1cdbg sxloryaswi
18 Oct 23
Registration of securities for employees
5:10pm